This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Zydelig
  • /
  • A Phase II, Non-Randomized, Single Institution, Cl...
Clinical trial

A Phase II, Non-Randomized, Single Institution, Clinical Trial of Signal Transduction Inhibitors, Ibrutinib or Idelalisib, to Treat Patients With Persistent or Relapsed B-Cell Malignancies Following Allogeneic Hematopoietic Cell Transplantation

Read time: 2 mins
Last updated:1st Mar 2016
Identifier: NCT02662296
This phase II trial studies how well ibrutinib or idelalisib works in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma that is persistent or has returned (relapsed) after donor stem cell transplant. Ibrutinib and idelalisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Category Value
Date last updated at source 2016-11-28
Study type(s) Interventional
Expected enrolment 50
Study start date 2016-03-01
Estimated primary completion date 2022-02-01

View full details